The Justice Department said that British pharma giant GlaxoSmithKline has agreed to pay a $150 million fine to settle fraud charges stemming from its pricing and marketing of two antinausea drugs. The company is accused of inflating the prices it charged Medicaid and Medicare programs for Zofran and Kytril. The two drugs are commonly used to combat nausea caused by radiation treatments. story [1]
Links:
[1] http://www.nytimes.com/2005/09/21/business/21glaxo.html